• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

波兰和国际上治疗成年囊性纤维化患者的费用。

Costs of treatment of adult patients with cystic fibrosis in Poland and internationally.

机构信息

Department of Pharmacoeconomics and Social Pharmacy, Poznań University of Medical Sciences, Dąbrowskiego 79 St., 60-529 Poznań, Poland.

Department of Pharmacoeconomics and Social Pharmacy, Poznań University of Medical Sciences, Dąbrowskiego 79 St., 60-529 Poznań, Poland.

出版信息

Public Health. 2017 Jul;148:49-55. doi: 10.1016/j.puhe.2017.03.003. Epub 2017 Apr 7.

DOI:10.1016/j.puhe.2017.03.003
PMID:28404533
Abstract

OBJECTIVES

Despite its low prevalence, cystic fibrosis (CF) may have a considerable impact on healthcare system expenditures in terms of direct healthcare costs and lost productivity. This study was aimed at calculation of costs associated with CF treatment in Poland, as well as at comparison of average costs of treatment of CF patients in selected countries, taking into account the purchasing power parity.

STUDY DESIGN

Retrospective study.

METHODS

The researchers undertook a retrospective study of adult patients with CF taking into account the broadest social perspective possible. Medical and non-medical direct costs as well as indirect costs were calculated. CF costs estimated by researchers from other countries over the last 15 years were also compared.

RESULTS

Total annual treatment cost per one CF patient in Poland was on average EUR 19,581.08. Costs of treatment of CF patients over the last 15 years varied between the countries and ranged from EUR 23,330.82 in Bulgaria to EUR 68,696.42 in the United States.

CONCLUSIONS

CF is an international problem. The data in this study could be the baseline for integrated and harmonised approaches for periodical assessment of the future impact of new public policies and interventions for rare diseases at the national and international levels.

摘要

目的

尽管囊性纤维化(CF)的患病率较低,但就直接医疗成本和生产力损失而言,其对医疗保健系统支出可能具有相当大的影响。本研究旨在计算波兰 CF 治疗相关费用,并考虑购买力平价,比较选定国家 CF 患者治疗的平均费用。

研究设计

回顾性研究。

方法

研究人员对成年 CF 患者进行了回顾性研究,尽可能从广泛的社会角度考虑。计算了医疗和非医疗直接成本以及间接成本。还比较了过去 15 年来其他国家研究人员估算的 CF 成本。

结果

波兰每位 CF 患者的年平均治疗费用为 19581.08 欧元。过去 15 年各国 CF 患者的治疗费用存在差异,从保加利亚的 23330.82 欧元到美国的 68696.42 欧元不等。

结论

CF 是一个国际性问题。本研究中的数据可以作为基准,用于定期评估新的公共政策和干预措施对国家和国际层面罕见病未来影响的综合和协调方法。

相似文献

1
Costs of treatment of adult patients with cystic fibrosis in Poland and internationally.波兰和国际上治疗成年囊性纤维化患者的费用。
Public Health. 2017 Jul;148:49-55. doi: 10.1016/j.puhe.2017.03.003. Epub 2017 Apr 7.
2
Social and economic costs and health-related quality of life in non-institutionalised patients with cystic fibrosis in the United Kingdom.英国非住院囊性纤维化患者的社会经济成本及健康相关生活质量
BMC Health Serv Res. 2015 Sep 28;15:428. doi: 10.1186/s12913-015-1061-3.
3
Cost of illness of cystic fibrosis in Germany: results from a large cystic fibrosis centre.德国囊性纤维化疾病负担:来自大型囊性纤维化中心的结果。
Pharmacoeconomics. 2012 Sep 1;30(9):763-77. doi: 10.2165/11588870-000000000-00000.
4
The Economic Burden of Cystic Fibrosis in Germany from a Payer Perspective.从支付者角度看德国囊性纤维化的经济负担。
Pharmacoeconomics. 2019 Aug;37(8):1029-1039. doi: 10.1007/s40273-019-00797-2.
5
Social/economic costs and health-related quality of life in patients with cystic fibrosis in Europe.欧洲囊性纤维化患者的社会/经济成本及与健康相关的生活质量
Eur J Health Econ. 2016 Apr;17 Suppl 1:7-18. doi: 10.1007/s10198-016-0781-6. Epub 2016 Apr 8.
6
Cystic fibrosis: cost of illness and considerations for the economic evaluation of potential therapies.囊性纤维化:疾病成本及潜在疗法经济评估的考量因素
Pharmacoeconomics. 2003;21(14):1001-24. doi: 10.2165/00019053-200321140-00002.
7
Cost-of-illness analysis and regression modeling in cystic fibrosis: a retrospective prevalence-based study.成本-疾病分析与回归建模在囊性纤维化中的应用:一项基于患病率的回顾性研究。
Eur J Health Econ. 2017 Jan;18(1):73-82. doi: 10.1007/s10198-015-0759-9. Epub 2016 Jan 7.
8
Measuring the burden of cystic fibrosis: A scoping review.测量囊性纤维化负担:范围综述。
J Cyst Fibros. 2024 Sep;23(5):823-830. doi: 10.1016/j.jcf.2023.11.014. Epub 2023 Dec 3.
9
Socioeconomic burden of cystic fibrosis in Canada.加拿大囊性纤维化的社会经济负担。
BMJ Open Respir Res. 2024 Aug 9;11(1):e002309. doi: 10.1136/bmjresp-2024-002309.
10
Estimating Direct Cost of Cystic Fibrosis Care Using Irish Registry Healthcare Resource Utilisation Data, 2008-2012.利用爱尔兰登记处的医疗资源利用数据估算囊性纤维化护理的直接成本,2008-2012 年。
Pharmacoeconomics. 2017 Oct;35(10):1087-1101. doi: 10.1007/s40273-017-0530-4.

引用本文的文献

1
Factors associated with frequent high-cost individuals with cystic fibrosis and their healthcare utilization and cost patterns.与囊性纤维化频繁高额费用个体及其医疗利用和费用模式相关的因素。
Sci Rep. 2023 Jun 1;13(1):8910. doi: 10.1038/s41598-023-35942-7.
2
Fat-Soluble Vitamins in Standard vs. Liposomal Form Enriched with Vitamin K2 in Cystic Fibrosis: A Randomized Multi-Center Trial.标准剂型与脂质体剂型富含维生素K2的脂溶性维生素在囊性纤维化患者中的应用:一项随机多中心试验
J Clin Med. 2022 Jan 17;11(2):462. doi: 10.3390/jcm11020462.
3
Cost-of-illness studies in rare diseases: a scoping review.
罕见病疾病负担研究:范围综述。
Orphanet J Rare Dis. 2021 Apr 13;16(1):178. doi: 10.1186/s13023-021-01815-3.
4
Reflections on the Importance of Cost of Illness Analysis in Rare Diseases: A Proposal.关于罕见病疾病经济负担分析重要性的思考:建议
Int J Environ Res Public Health. 2021 Jan 26;18(3):1101. doi: 10.3390/ijerph18031101.
5
The Economic Burden of Cystic Fibrosis in Germany from a Payer Perspective.从支付者角度看德国囊性纤维化的经济负担。
Pharmacoeconomics. 2019 Aug;37(8):1029-1039. doi: 10.1007/s40273-019-00797-2.